Xiujuan Xia1, Xianjin Chen2, Xue Li3, Changlin Sui3. 1. Department of Dermatology, Qingdao University Medical College Affiliated Yantai Yuhuangding Hospital, No 20, Yuhuangding East Road, Zhifu district, Yantai, Shandong province, China. snowli211@163.com. 2. Department of Dermatology, Qingdao University Medical College Affiliated Yantai Yuhuangding Hospital, No 20, Yuhuangding East Road, Zhifu district, Yantai, Shandong province, China. chenxj1975@gmail.com. 3. Department of Dermatology, Qingdao University Medical College Affiliated Yantai Yuhuangding Hospital, No 20, Yuhuangding East Road, Zhifu district, Yantai, Shandong province, China.
Abstract
BACKGROUND: Botulinum toxin type A (BoNT/A) has been used in aesthetic applications worldwide, including glabellar lines. Currently, four BoNT/A preparations were approved for the improvement of moderate-to-severe glabellar lines: onabotulinumtoxinA, abobotulinumtoxinA, incobotulinumtoxinA, and prabotulinumtoxinA. DaxibotulinumtoxinA is a new form of BoNT/A drug that is developed in clinical application. We performed this network meta-analysis (NMA) to assess the efficacy and safety of all these different BoNT/A formulations for treating glabellar lines. METHODS: The investigators searched randomized controlled trials (RCTs) using the Medical Subject Headings (MeSH) terms "botulinum toxin" and "glabellar lines." We searched the relevant studies in electronic databases as following: PubMed, Elsevier, EMBASE and the Cochrane Library. The end points included the percentage of subjects with a glabellar line severity (GLS) score of none (0) or mild (1), and the percentage of subjects achieving ≥ 1-point and 2-point improvement in glabellar line severity at maximum frown at approximately month 1 by the investigators' assessment. RESULTS: All formulations of BoNT/A were far superior to placebo in efficacy. DaxibotulinumtoxinA was the only treatment that significantly increased the proportion of subjects achieving ≥ 1 point improvement in GLS score compared with other BoNT/A formulations. Moreover, daxibotulinumtoxinA was ranked the highest for the proportion of subjects achieving ≥ 2-point improvement in GLS score. No significant differences were revealed for the incidence of any adverse events (AEs) that related to treatment or drug among all BoNT/A preparations. CONCLUSION: The overall results of this NMA suggested that daxibotulinumtoxinA is a new BoNT/A preparation that may be not only more effective but also well-tolerated for the treatment of glabellar lines. LEVEL OF EVIDENCE I: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
BACKGROUND: Botulinum toxin type A (BoNT/A) has been used in aesthetic applications worldwide, including glabellar lines. Currently, four BoNT/A preparations were approved for the improvement of moderate-to-severe glabellar lines: onabotulinumtoxinA, abobotulinumtoxinA, incobotulinumtoxinA, and prabotulinumtoxinA. DaxibotulinumtoxinA is a new form of BoNT/A drug that is developed in clinical application. We performed this network meta-analysis (NMA) to assess the efficacy and safety of all these different BoNT/A formulations for treating glabellar lines. METHODS: The investigators searched randomized controlled trials (RCTs) using the Medical Subject Headings (MeSH) terms "botulinum toxin" and "glabellar lines." We searched the relevant studies in electronic databases as following: PubMed, Elsevier, EMBASE and the Cochrane Library. The end points included the percentage of subjects with a glabellar line severity (GLS) score of none (0) or mild (1), and the percentage of subjects achieving ≥ 1-point and 2-point improvement in glabellar line severity at maximum frown at approximately month 1 by the investigators' assessment. RESULTS: All formulations of BoNT/A were far superior to placebo in efficacy. DaxibotulinumtoxinA was the only treatment that significantly increased the proportion of subjects achieving ≥ 1 point improvement in GLS score compared with other BoNT/A formulations. Moreover, daxibotulinumtoxinA was ranked the highest for the proportion of subjects achieving ≥ 2-point improvement in GLS score. No significant differences were revealed for the incidence of any adverse events (AEs) that related to treatment or drug among all BoNT/A preparations. CONCLUSION: The overall results of this NMA suggested that daxibotulinumtoxinA is a new BoNT/A preparation that may be not only more effective but also well-tolerated for the treatment of glabellar lines. LEVEL OF EVIDENCE I: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
Authors: Michael A C Kane; Michael H Gold; William P Coleman; Derek H Jones; Emil A Tanghetti; Tina S Alster; Tom E Rohrer; Cheryl M Burgess; Ava T Shamban; Eleanor Finn Journal: Dermatol Surg Date: 2015-11 Impact factor: 3.398
Authors: Kwang Ho Yoo; Yang Won Lee; Ji Su Lee; Soon Hyo Kwon; Chang Hun Huh; Beom Joon Kim Journal: Dermatol Surg Date: 2021-03-01 Impact factor: 3.398
Authors: Marion Moers-Carpi; Thomas Dirschka; Gabrielle Feller-Heppt; Said Hilton; Klaus Hoffmann; Wolfgang G Philipp-Dormston; Anita Rütter; Kelvin Tan; Mary Ann Chapman; Antony Fulford-Smith Journal: J Cosmet Laser Ther Date: 2012-11-15 Impact factor: 2.247
Authors: Patricia Ogilvie; Alexander Z Rivkin; Steven Dayan; Steven G Yoelin; Barry M Weichman; Julie K Garcia Journal: Dermatol Surg Date: 2019-05 Impact factor: 3.398
Authors: C William Hanke; Rhoda S Narins; Fredric Brandt; Joel L Cohen; Lisa M Donofrio; Jeanine Downie; Moritz Heinz; Laura Harrington; David H McDaniel; Mark Nestor; Joel Schlessinger; Andrea Schlöbe; Amy Taub; Robert A Weiss Journal: Dermatol Surg Date: 2013-03-18 Impact factor: 3.398
Authors: B J Kim; H H Kwon; S Y Park; S U Min; J Y Yoon; Y M Park; S H Seo; J Y Ahn; H K Lee; D H Suh Journal: J Eur Acad Dermatol Venereol Date: 2014-03-05 Impact factor: 6.166
Authors: Joel Schlessinger; Joel L Cohen; Ava Shamban; Carolyn Jacob; Kian Karimi; Corey Maas; Vanessa Lane; Sarah Coquis-Knezek; Matthew Meckfessel Journal: Dermatol Surg Date: 2021-04-01 Impact factor: 2.914